全文获取类型
收费全文 | 39266篇 |
免费 | 3979篇 |
国内免费 | 1322篇 |
专业分类
耳鼻咽喉 | 176篇 |
儿科学 | 2005篇 |
妇产科学 | 778篇 |
基础医学 | 3569篇 |
口腔科学 | 797篇 |
临床医学 | 4670篇 |
内科学 | 6828篇 |
皮肤病学 | 255篇 |
神经病学 | 2004篇 |
特种医学 | 1450篇 |
外国民族医学 | 9篇 |
外科学 | 5583篇 |
综合类 | 5240篇 |
现状与发展 | 4篇 |
一般理论 | 1篇 |
预防医学 | 4142篇 |
眼科学 | 1007篇 |
药学 | 3262篇 |
13篇 | |
中国医学 | 1254篇 |
肿瘤学 | 1520篇 |
出版年
2024年 | 89篇 |
2023年 | 637篇 |
2022年 | 1326篇 |
2021年 | 1612篇 |
2020年 | 1498篇 |
2019年 | 1477篇 |
2018年 | 1443篇 |
2017年 | 1330篇 |
2016年 | 1316篇 |
2015年 | 1291篇 |
2014年 | 2386篇 |
2013年 | 3044篇 |
2012年 | 2096篇 |
2011年 | 2295篇 |
2010年 | 1881篇 |
2009年 | 1841篇 |
2008年 | 1954篇 |
2007年 | 1925篇 |
2006年 | 1739篇 |
2005年 | 1674篇 |
2004年 | 1463篇 |
2003年 | 1284篇 |
2002年 | 1061篇 |
2001年 | 947篇 |
2000年 | 848篇 |
1999年 | 675篇 |
1998年 | 595篇 |
1997年 | 623篇 |
1996年 | 514篇 |
1995年 | 418篇 |
1994年 | 402篇 |
1993年 | 332篇 |
1992年 | 296篇 |
1991年 | 259篇 |
1990年 | 207篇 |
1989年 | 187篇 |
1988年 | 176篇 |
1987年 | 158篇 |
1986年 | 119篇 |
1985年 | 187篇 |
1984年 | 163篇 |
1983年 | 132篇 |
1982年 | 130篇 |
1981年 | 126篇 |
1980年 | 108篇 |
1979年 | 62篇 |
1978年 | 52篇 |
1977年 | 50篇 |
1976年 | 41篇 |
1975年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
51.
Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage. 相似文献
52.
目的 探讨中国人过氧化物酶体增殖物激活受体γ(PPARγ)基因外显子6 C161T多态性与糖皮质激素性骨质疏松症(GIO)的相关关系。方法 应用聚合酶链反应-限制性片段长度多态性(PCR-RELP)方法测定208例正常健康人(Ⅰ组)、168例非GIO患者(Ⅱ组)和104例GIO患者(Ⅲ组)PPARγ基因外显子6 C161T的基因型。应用双能X线骨密度仪(DEXA)测定股骨、腰椎等部位的骨密度。 结果 外显子6 C161T有CC、CT、TT 3种基因型。GIO组CC基因型频率显著低于正常对照组;CT和TT基因型频率显著高于正常对照组。非GIO组、应用激素组(GIO组+非GIO组)与正常对照组比较,各基因型频率差异均无统计学意义。正常对照组C161T的CC基因型组各部位的骨密度有高于CT和TT基因型组的趋势,但差异无统计学意义。非GIO组和GIO组C161T的CC基因型组腰椎的骨密度明显高于CT和TT基因型组 (P < 0.05),分别为非GIO组CC型(1.04±0.17) g/cm2,CT+TT型(1.02±0.07) g/cm2;GIO组CC型(0.94±0.12) g/cm2,CT+TT型(0.83±0.08) g/cm2。经年龄、体重指数等因素校正后,差异仍有统计学意义(P < 0.05)。 结论 PPARγ基因C161T基因型在正常人和应用激素患者之间无明显差异,它可能与肾小球肾炎的发病无关。C161T基因型在GIO组和正常对照组之间差异有统计学意义,它可能与糖皮质激素性骨质疏松症的发病有关。PPARγ基因C161T多态性与应用糖皮质激素患者腰椎的骨密度有关。等位基因C可能是骨量的保护因子,它可能与应用糖皮质激素后骨量的丢失有关。 相似文献
53.
54.
G Ferretti T Bacchetti R A Rabini A Vignini L Nanetti C Moroni L Mazzanti 《Diabetic medicine》2006,23(7):808-813
BACKGROUND: Homocysteine (Hcy) is an independent risk factor for cardiovascular disease (CVD). Individuals with Type 1 and Type 2 diabetes are more susceptible to the effects of homocysteine than non-diabetic subjects. The interaction between homocysteine-thiolactone (Hcy-thiolactone), a reactive product of Hcy, and low-density lipoproteins (LDL) induces the formation of homocystamide-LDL adducts (Hcy-LDL) and it has been suggested that homocysteinylation could increase atherogenicity of lipoproteins. AIM: The aim of the study was to compare the effect of in vitro homocysteinylation of LDL isolated from healthy control subjects (C-LDL) and from Type 1 diabetic patients (DM-LDL) and to investigate the effect of homocysteinylated LDL (Hcy-C-LDL and Hcy-DM-LDL) on peroxynitrite production of endothelial cells. METHODS: The in vitro homocysteinylation of LDL isolated from control (n = 12) and DM subjects (n = 12) was carried out by incubating lipoproteins with Hcy-thiolactone. The reaction was verified by quantifying the increase in sulphydryl groups (-SH groups) in Hcy-LDL with respect to control LDL. Control and homocysteinylated LDL were incubated with human aortic endothelial cells (HAEC) in culture. Peroxynitrite production in cells treated in different experimental conditions was assayed by a fluorimetric method. RESULTS: The increase in -SH groups after incubation with homocysteine was greater in LDL from diabetic subjects compared with LDL from control subjects (P < 0.001). In addition, peroxynitrite production from HAEC incubated with Hcy-LDL from diabetic patients was greater than after incubation with Hcy-LDL from control subjects and untreated LDL from diabetic patients (P < 0.001). CONCLUSIONS: These results show that LDL from diabetic patients is more susceptible to in vitro homocysteinylation than LDL from non-diabetic individuals and demonstrate that the compositional changes in Hcy-LDL from diabetic subjects have cytotoxic effects on human endothelial cells. 相似文献
55.
目的 探讨肿瘤微血管密度(MVD)与肝细胞性肝癌临床病理及预后的关系。方法对30例肝细胞性肝癌根治性切除病理组织切片进行苏木精伊红染色.并用CD34单克隆抗体进行免疫组化染色,计数被CD34抗体染色的肿瘤血管内皮细胞数,以测定MVD。对MVD与临床病理因素及术后生存率关系进行分析。结果 单因素分析结果表明.MVD水平与肿瘤大小、TNM分期都是影响肝细胞性肝癌预后的因素;多因素分析结果表明.肝癌大小及肿瘤分期是肝细胞性肝癌独立预后因素。结论 MVD是肝细胞性肝癌一种预后因素。 相似文献
56.
Masao Akagi Shunji Nishimura Kohji Yoshida Takumi Kakinuma Tatsuya Sawamura Hiroshi Munakata Chiaki Hamanishi 《Journal of orthopaedic research》2006,24(8):1782-1790
Mechanical stimulation is known to be an essential factor in the regulation of cartilage metabolism. We tested the hypothesis that expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) can be modulated by cyclic tensile stretch load in chondrocytes. Cyclic loading of repeated stretch stress at 10 cycles per minute with 10 kPa of stress for 6 h induced expression of LOX-1 to 2.6 times control in cultured bovine articular chondrocytes, equivalent to the addition of 10 microg/mL oxidized low density lipoprotein (ox-LDL) (2.4 times control). Application of the cyclic load to the chondrocytes along with 10 microg/mL ox-LDL resulted in synergistically increased LOX-1 expression to 6.3 times control. Individual application of cyclic loading and 10 microg/mL ox-LDL significantly suppressed chondrocytes viability (84.6% +/- 3.4% and 80.9% +/- 3.2% of control at 24 h, respectively; n = 3; p < 0.05) and proteoglycan synthesis [81.0% +/- 7.1% and 85.7% +/- 5.2% of control at 24 h, respectively; p < 0.05 when compared with 94.6% +/- 4.6% for native-LDL (n = 3)]. Cyclic loading and 10 microg/mL ox-LDL synergistically affected cell viability and proteoglycan synthesis, which were significantly suppressed to 45.6% +/- 4.9% and 48.7% +/- 6.7% of control at 24 h, respectively (n = 3; p < 0.01 when compared with individual application of cyclic loading or 10 microg/mL ox-LDL). In this study, we demonstrated synergistic effects of cyclic tensile stretch load and ox-LDL on cell viability and proteoglycan synthesis in chondrocytes, which may be mediated through enhanced expression of LOX-1 and which has important implications in the progression of cartilage degeneration in osteoarthritis. 相似文献
57.
高果糖诱导IR大鼠模型血清脂质代谢的改变及意义 总被引:4,自引:0,他引:4
目的: 评估高果糖膳食对机体胰岛素敏感性及血清脂质代谢的影响及意义.方法:以高果糖膳食(果糖占总热量34.5%)诱导并经钳夹技术证实建立胰岛素抵抗(IR)大鼠模型,生化比色法测定血清游离脂肪酸(FFA),生化酶法测定血清甘油三酯(TG)及总胆固醇(TC).结果:高果糖膳食喂养4周后,实验组大鼠葡萄糖输注率由(11.5±0.6)mg/kg·min-1下降至(6.6±0.4)mg/kg·min-1(P<0.01);血清FFA由(0.45±0.09)mmol/L增至(0.78±0.19)mmol/L(P<0.01);TG由(0.54±0.10)mmol/L增至(0.96±0.22)mmol/L(P<0.01);TC由(1.96±0.32)mmol/L增至(2.42±0.21)mmol/L(P<0.01).结论:高果糖膳食可导致机体严重IR,是建立IR大鼠模型的有效手段;该模型同时伴有血清脂代谢各相关指标的明显异常,血脂的变化既是IR的结果,也是IR向纵深发展的原因和必要条件. 相似文献
58.
59.
目的 :观察临床应用卡维地洛能否降低冠心病患者血浆氧化修饰低密度脂蛋白 (Ox LDL)水平。方法 :选择确诊冠心病患者及年龄、性别相匹配的正常对照组各 30例。冠心病组卡维地洛平均用量为 (10± 2 .5 )mg/d ,共 4个月 ,于服药前、服药后2个月及 4个月 ,分别采集清晨空腹血 ,以检测Ox LDL ,丙二醛 (MDA)。结果 :冠心病组的Ox LDL、MDA水平显著高于对照组 ,在用药后 2及 4个月冠心病组Ox LDL较用药前有显著降低 (P <0 .0 5 ) ,MDA显示出类似的趋势 (P <0 .0 1)。结论 :卡维地洛具有抗氧化作用 ,可以降低冠心病患者血浆Ox LDL水平。 相似文献
60.
P. V. Luoma A. Rautio J. Steng»rd E. A. Sotaniemi J. Marniemi 《European journal of clinical pharmacology》1990,38(6):625-627
Summary Serum high density lipoprotein (HDL) subfractions HDL2 and HDL3, apolipoproteins, and plasma antipyrine clearance (AP-CL) rate, an index of liver microsomal enzyme activity, were determined in 21 healthy subjects. High HDL cholesterol and HDL2 cholesterol concentrations and HDL cholesterol/cholesterol and HDL2/HDL3 cholesterol ratios were associated with high AP-CL. Phenobarbital enhanced antipyrine elimination and increased the apolipoprotein A-I/A-II ratio. Subjects who had high AP-CL had a more antiatherogenic HDL subfraction and apolipoprotein profile than those with low AP-CL. 相似文献